# Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Source: https://onco.cc/trials/nct05918302/  
OnCo record `nct05918302` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 177Lu-edotreotide and everolimus in lung cancer, run by Grupo Espanol de Tumores Neuroendocrinos, now recruiting.

## Summary

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. is a phase 3, randomised interventional study registered as NCT05918302 by Grupo Espanol de Tumores Neuroendocrinos, with a registry enrolment figure of 170 participants, started 2023-10-27 and due to reach its primary completion in 2029-03. Interventions recorded: 177Lu-edotreotide; Everolimus. Conditions listed: Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "Patients who have histologically confirmed metastatic or locally advanced unresectable well/moderately differentiated; World Health Organization (WHO\]) 2015 criteria; neuroendocrine tumor of lung (typical and atypical carcinoids) or thymus origin either functioning or non-functioning". Sites: Belgium, France, Italy, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: LEVEL
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05918302
- Phase: 3
- Setting: Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT05918302: https://clinicaltrials.gov/study/NCT05918302

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [177Lu-edotreotide](https://onco.cc/drugs/itm-11/), [Everolimus](https://onco.cc/drugs/everolimus/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05918302.json